Fulcrum Therapeutics Dirección

Dirección controles de criterios 1/4

Fulcrum Therapeutics' El consejero delegado es Alex Sapir , nombrado en Jul 2023, tiene un mandato de menos de un año. posee directamente 0.07% de las acciones de la empresa, con un valor de $490.41K . La antigüedad media del equipo directivo y del consejo de administración es de 1.6 años y 7.2 años, respectivamente.

Información clave

Alex Sapir

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.07%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11

Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%

May 12

We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely

May 07

Fulcrum Therapeutics beats on revenue

May 06

CEO

Alex Sapir (56 yo)

less than a year

Permanencia

Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexander Sapir	CEO, President & Director	less than a year	sin datos	0.070% $ 297.6k
Bradley Bernstein	Founder	no data	sin datos	sin datos
Michael Green	Founder	no data	sin datos	sin datos
Rudolf Jaenisch	Founder	no data	sin datos	sin datos
Tsun-Huei Lee	Founder	no data	sin datos	sin datos
Danny Reinberg	Founder	no data	sin datos	sin datos
Alan Musso	Chief Financial Officer	less than a year	sin datos	sin datos
Gregory Tourangeau	Controller & Principal Accounting Officer	2.1yrs	sin datos	0.015% $ 64.3k
Jeffrey Jacobs	Chief Scientific Officer	1.4yrs	sin datos	sin datos
Curtis Oltmans	Senior VP	3.4yrs	US$1.36m	sin datos
Paul Bruno	Senior Vice President of Business & Corporate Development	1.7yrs	sin datos	sin datos
Kim Hazen	Chief People Officer	3.4yrs	sin datos	sin datos

1.7yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: FULCEl equipo directivo de la empresa no se considera experimentado ( 1.3 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexander Sapir	CEO, President & Director	less than a year	sin datos	0.070% $ 297.6k
James Arthur Geraghty	Independent Director	7.8yrs	US$128.84k	0.15% $ 622.7k
H. Sweeney	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Collins	Independent Director	7.3yrs	US$123.34k	0.038% $ 161.8k
Katina Dorton	Independent Director	4.3yrs	US$133.34k	0% $ 0
Leslie Leinwand	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Gould	Director	7.8yrs	US$118.34k	0.81% $ 3.4m
Alan Ezekowitz	Independent Director	7.3yrs	US$128.34k	0.047% $ 198.6k
Kathryn Haviland	Independent Chair of the Board	5.8yrs	US$154.37k	0% $ 0
Jeffrey Statland	Member of FSHD Clinical Advisory Board	no data	sin datos	sin datos
Rabi Tawil	Member of FSHD Clinical Advisory Board	no data	sin datos	sin datos
Baziel van Engelen	Member of FSHD Clinical Advisory Board	no data	sin datos	sin datos

7.3yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de FULC se considera experimentada (6.9 años de antigüedad promedio).

Fulcrum Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Fulcrum Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Fulcrum Therapeutics, Inc. Announces Executive Changes

CEO, President & Director recently bought US$492k worth of stock

Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023

Fulcrum Therapeutics, Inc. Chief Executive Officer Changes

Insufficient new directors

Recent updates

Fulcrum Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Fulcrum Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

CEO, President & Director recently bought US$492k worth of stock

Consensus revenue estimates fall by 15%

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.8% to US$11.21

Fulcrum Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

New major risk - Share price stability

Price target increased by 31% to US$10.57

Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease

Consensus revenue estimates increase by 11%

Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Value Index

Levi & Korsinsky, LLP Notifies Fulcrum Therapeutics, Inc. Investors of Class Action Lawsuit and Upcoming Deadline

Consensus revenue estimates decrease by 31%, EPS upgraded

Fulcrum Therapeutics, Inc. Chief Executive Officer Changes

Price target decreased by 22% to US$7.56

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 17% to US$18.75

Price target increased by 11% to US$24.38

Insufficient new directors

President notifies of intention to sell stock

Fulcrum Therapeutics, Inc. Announces Resignation of Bryan Stuart from the Board of Directors

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Consensus forecasts updated

Price target decreased to US$25.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. Announces Management Changes

Fulcrum Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Fulcrum Therapeutics, Inc. Announces Resignation of Judith A. Dunn as President, Research and Development

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 Redux4 Study

Price target increased to US$30.71

Consensus revenue estimates fall by 17%

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Fulcrum Therapeutics, Inc. Promotes Mel Hayes to the Chief Operating Officer

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Fulcrum Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Fulcrum Therapeutics Announces Executive Changes

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Fulcrum Therapeutics, Inc. Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Fulcrum Therapeutics Announces Proof-Of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1B Trial

Price target decreased to US$30.25

Consensus revenue estimates fall by 19%

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

First quarter 2022 earnings: EPS and revenues miss analyst expectations

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Fulcrum Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Director exercised options and sold US$1.5m worth of stock

Fulcrum Therapeutics, Inc. Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Fulcrum Therapeutics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans